NCT05269485CompletedPhase 2
Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-small Cell Lung Cancer: A Phase II Trial
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overall survival of 47.5 months, there still existed 38.5% and 6.9% patients who finally developed intra-thorax and extra-thorax recurrence respectively in long-term follow-up. The relatively low local control rate has been the bottleneck for further improvement of overall survival. Hypofraction radiotherapy has been validated to be able to increase the local control rate in two prospective trials. Therefore, this trial is designed to explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 19 Feb 2022
- Start date
- 1 Mar 2022
- Primary completion date
- 30 Jan 2024
- Lead sponsor
- Anhui Provincial Hospital
- Diseases
- Lung cancer
- NCT number
- NCT05269485
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 36
- From 1 Mar 2022 to the primary completion date, 30 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma;
Age
- Younger than 18 years old or older than 70 years old;
Other
- ECOG\>1;
- Mutant type of driven genes;
- Stage I and IV (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
- Surgically resectable;
- No signature of inform consent.
Who the study is looking for
- 18-70 years old;
- Eastern Cooperative Oncology Group (ECOG) 0-1;
- Non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma;
- Wild-type of driven genes;
- Stage II-III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and d Positron Emission Tomography (PET-CT);
- Surgically unresectable or deny of surgery;
- Signature of inform consent.
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Anhui Provicial Hospital Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.